Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers

NCT05412173 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Viral Infection
COVID-19

Interventions

DRUG: Molnupiravir

Sponsor

Valenta Pharm JSC